Corporate finance – silence therapeutics upsized funding for siRNA pipeline after Phase 2 win

Silence Therapeutics priced an upsized public offering expected to raise about $175 million, aiming to fund its short interfering RNA programs, including divesiran after the drug achieved a best-case outcome in a Phase 2 study for a rare leukemia. The financing comes after the company had proposed raising roughly $150 million, signaling strong demand for additional runway.